{
  "id": "401307a32edd8166",
  "title": "Biologics License Application for Subcutaneous Formulation of  LEQEMBI ( R ) ( lecanemab ) for the Treatment of Early Alzheimer Disease Accepted in China<BR / >",
  "description": "20260106T180000Z",
  "content": "",
  "source": "jcnnewswire.com",
  "source_url": "https://www.jcnnewswire.com/pressrelease/104466/3/Biologics-License-Application-for-Subcutaneous-Formulation-of-LEQEMBI(R)-(lecanemab)-for-the-Treatme",
  "published_at": "20260106T180000Z",
  "fetched_at": "2026-01-07T00:22:40.638561+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "china"
  ],
  "location": "Japan",
  "raw_data": {
    "url": "https://www.jcnnewswire.com/pressrelease/104466/3/Biologics-License-Application-for-Subcutaneous-Formulation-of-LEQEMBI(R)-(lecanemab)-for-the-Treatme",
    "url_mobile": "",
    "title": "Biologics License Application for Subcutaneous Formulation of  LEQEMBI ( R ) ( lecanemab ) for the Treatment of Early Alzheimer Disease Accepted in China<BR / >",
    "seendate": "20260106T180000Z",
    "socialimage": "",
    "domain": "jcnnewswire.com",
    "language": "English",
    "sourcecountry": "Japan"
  }
}